FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313444044> ?p ?o ?g. }

• W4313444044 endingPage "8" @default.
• W4313444044 startingPage "8" @default.
• W4313444044 abstract "In patients with long-term oral anticoagulant (OAC) therapy treated with percutaneous coronary intervention (PCI), the 2020 European guidelines recommend a dual antithrombotic therapy (DAT) combining an OAC and a single antiplatelet therapy (SAPT) for a period of 6 to 12 months according on the clinical context. Our study aims to assess real-life practices using data from the France PCI registry. All consecutive patients from the France PCI registry treated by PCI and on OAC therapy between 2014 and 2019 were included. Two groups of patients were determined. Patients with DAT (1 oral anticoagulant and SAPT) or a triple therapy (TAT) < 1 month were included in the DAT group. Patients with OAC and DAPT > 1 month constituted the TAT group. The primary endpoint was defined as significant bleeding according to the BARC classification (≥ 3) at one-year follow-up. The secondary endpoint was a composite endpoint of ischemic events including death, myocardial infarction, stroke, unscheduled revascularization or stent thrombosis. Two secondary analyses were performed using a 1:1 patient matching with a propensity score to balance the 2 populations comparing DAT vs. TAT and vitamin K antagonist (VKA) vs. direct OAC (DOAC). Between 2014 and 2019, 5768 consecutive patients were discharged with TAT (n = 3993; 69.2%) or DAT (n = 1775; 30.8%). The incidence of bleeding events was significantly increased in the DAT group as compared to the TAT group (7.1% vs. 5.1%, HR: 1.41; 95% CI: 1.41–1.76; P < 0.01). In contrast, there was no significant difference in the incidence of ischemic events (13.4% vs. 15.2%, HR: 0.88; 95% CI: 0.75–1.02; P = 0.08). After propensity score matching, there was no more significant difference in bleeding complications (7.0% vs. 5.4%, P = 0.09). On the other hand, the incidence of hemorrhagic events was significantly lower in patients on DOAC compared to those on VKA (4.2% vs. 7.1%, P < 0.01), the rate of ischemic events did not differ significantly between the two groups (13.6% vs. 14.3%, P = 0.67). The results of our study suggest that DAT is used in France in only 30% of cases and unlike randomized studies, does not reduce bleeding complications compared to TAT. Ischemic complications were similar between the 2 strategies. Furthermore, our study underlines the superiority of DOAC over VKA in patients with OAC requiring PCI." @default.
• W4313444044 created "2023-01-06" @default.
• W4313444044 creator A5000570145 @default.
• W4313444044 creator A5011114575 @default.
• W4313444044 creator A5013940957 @default.
• W4313444044 creator A5033788369 @default.
• W4313444044 creator A5045539362 @default.
• W4313444044 creator A5050868612 @default.
• W4313444044 creator A5057532729 @default.
• W4313444044 creator A5081871205 @default.
• W4313444044 creator A5085236746 @default.
• W4313444044 date "2023-01-01" @default.
• W4313444044 modified "2023-09-26" @default.
• W4313444044 title "Safety and efficacy of dual vs. triple antithrombotic therapy in patients with indication of anticoagulation treated by PCI: A retrospective analysis of the FRANCE PCI registry" @default.
• W4313444044 doi "https://doi.org/10.1016/j.acvdsp.2022.10.007" @default.
• W4313444044 hasPublicationYear "2023" @default.
• W4313444044 type Work @default.
• W4313444044 citedByCount "0" @default.
• W4313444044 crossrefType "journal-article" @default.
• W4313444044 hasAuthorship W4313444044A5000570145 @default.
• W4313444044 hasAuthorship W4313444044A5011114575 @default.
• W4313444044 hasAuthorship W4313444044A5013940957 @default.
• W4313444044 hasAuthorship W4313444044A5033788369 @default.
• W4313444044 hasAuthorship W4313444044A5045539362 @default.
• W4313444044 hasAuthorship W4313444044A5050868612 @default.
• W4313444044 hasAuthorship W4313444044A5057532729 @default.
• W4313444044 hasAuthorship W4313444044A5081871205 @default.
• W4313444044 hasAuthorship W4313444044A5085236746 @default.
• W4313444044 hasConcept C126322002 @default.
• W4313444044 hasConcept C141071460 @default.
• W4313444044 hasConcept C151730666 @default.
• W4313444044 hasConcept C168563851 @default.
• W4313444044 hasConcept C17923572 @default.
• W4313444044 hasConcept C203092338 @default.
• W4313444044 hasConcept C2776301958 @default.
• W4313444044 hasConcept C2776704044 @default.
• W4313444044 hasConcept C2777015399 @default.
• W4313444044 hasConcept C2779161974 @default.
• W4313444044 hasConcept C2779343474 @default.
• W4313444044 hasConcept C2780400711 @default.
• W4313444044 hasConcept C45393284 @default.
• W4313444044 hasConcept C500558357 @default.
• W4313444044 hasConcept C71924100 @default.
• W4313444044 hasConcept C86803240 @default.
• W4313444044 hasConceptScore W4313444044C126322002 @default.
• W4313444044 hasConceptScore W4313444044C141071460 @default.
• W4313444044 hasConceptScore W4313444044C151730666 @default.
• W4313444044 hasConceptScore W4313444044C168563851 @default.
• W4313444044 hasConceptScore W4313444044C17923572 @default.
• W4313444044 hasConceptScore W4313444044C203092338 @default.
• W4313444044 hasConceptScore W4313444044C2776301958 @default.
• W4313444044 hasConceptScore W4313444044C2776704044 @default.
• W4313444044 hasConceptScore W4313444044C2777015399 @default.
• W4313444044 hasConceptScore W4313444044C2779161974 @default.
• W4313444044 hasConceptScore W4313444044C2779343474 @default.
• W4313444044 hasConceptScore W4313444044C2780400711 @default.
• W4313444044 hasConceptScore W4313444044C45393284 @default.
• W4313444044 hasConceptScore W4313444044C500558357 @default.
• W4313444044 hasConceptScore W4313444044C71924100 @default.
• W4313444044 hasConceptScore W4313444044C86803240 @default.
• W4313444044 hasIssue "1" @default.
• W4313444044 hasLocation W43134440441 @default.
• W4313444044 hasOpenAccess W4313444044 @default.
• W4313444044 hasPrimaryLocation W43134440441 @default.
• W4313444044 hasRelatedWork W2058436193 @default.
• W4313444044 hasRelatedWork W2114392716 @default.
• W4313444044 hasRelatedWork W2376962719 @default.
• W4313444044 hasRelatedWork W2761804449 @default.
• W4313444044 hasRelatedWork W2763816051 @default.
• W4313444044 hasRelatedWork W2822274293 @default.
• W4313444044 hasRelatedWork W2891501215 @default.
• W4313444044 hasRelatedWork W2905317511 @default.
• W4313444044 hasRelatedWork W3100181024 @default.
• W4313444044 hasRelatedWork W3215196831 @default.
• W4313444044 hasVolume "15" @default.
• W4313444044 isParatext "false" @default.
• W4313444044 isRetracted "false" @default.
• W4313444044 workType "article" @default.